Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178895 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL25143 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178890 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL2182769 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL17746959 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178762 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178759 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178761 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178758 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178892 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122011102-A | Cyclic peptide ligand of target asialoglycoprotein receptor, pharmaceutically acceptable salt thereof and application and pharmaceutical composition thereof | 浙江大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20260117106-A1 | ANTI-FREEZE COMPOSITION BASED ON 2D AMPHIPHILIC PEPTIDE NANOSTRUCTURES | GWANGJU INST SCIENCE & TECH (KR) | 2026-04-30 | — | — | US | disclosed |
| CN-118028329-A | Preparation method and application of xanthomonas oryzae NuoEF complex protein crystal | 江苏省中国科学院植物研究所 | 2024-05-14 | — | — | CN | disclosed |
| EP-4305162-A1 | MICELLAR CATALYSIS | University of Newcastle Upon Tyne (GB) | 2024-01-17 | — | — | EP | disclosed |
| CN-116964200-A | Micelle catalysis | 泰恩河畔纽卡斯尔大学 | 2023-10-27 | — | — | CN | disclosed |
| CN-112851755-B | Linear lipopeptide compound and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-09-01 | — | — | CN | disclosed |
| CN-114763369-A | Aliphatic peptide chain and Fab-aliphatic chain conjugate | 正大天晴药业集团股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| CN-113615700-A | Application of parthenolide derivative in prevention and treatment of bacterial blight of rice | 江苏省中国科学院植物研究所 | 2021-11-09 | — | — | CN | disclosed |
| CN-107522779-B | Polypeptide having sugar chain attached thereto and pharmaceutical composition containing the same | 株式会社糖锁工学研究所 | 2021-10-26 | — | — | CN | disclosed |
| CN-112851755-A | Linear lipopeptide compound and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2021-05-28 | — | — | CN | disclosed |
| WO-2005000878-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004099774-A2 | PROCESSES FOR THE IDENTIFICATION OF MEDICAL TARGETS BY SCREENING AN ACTIVE AGENT FOR BINDING INTERACTIONS | CELLZOME AG (DE) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004031405-A1 | SUBSTRATES FOR O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2004-04-15 | — | — | WO | disclosed |
| US-6664231-B1 | Based on Domain III (amino acids 142-169) of bactericidal/ permeability-increasing protein; candida, aspergillus, cryptococcus | XOMA CORPORATION | 2003-12-16 | — | — | US | disclosed |
| US-6156730-A | Anti-fungal peptides | XOMA CORPORATION (US) | 2000-12-05 | — | — | US | disclosed |
| US-5858974-A | BACTERICIDAL/PERMEABILITY INCREASING PROTEIN | XOMA CORPORATION (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0839156-A1 | ANTI-FUNGAL PEPTIDES | Xoma Corporation (US) | 1998-05-06 | — | — | EP | disclosed |
| WO-1997004008-A1 | ANTI-FUNGAL PEPTIDES | XOMA CORPORATION (US) | 1997-02-06 | — | — | WO | disclosed |
| EP-0541663-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS HAVING GLYCOPROTEIN HORMONE AGONISTIC OR ANTAGONISTIC ACTIVITY | STICHTING CENTRAAL DIERGENEESKUNDIG INSTITUUT (NL) | 1993-05-19 | — | — | EP | disclosed |
| WO-1992002542-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS HAVING GLYCOPROTEIN HORMONE AGONISTIC OR ANTAGONISTIC ACTIVITY | STICHTING CENTRAAL DIERGENEESKUNDIG INSTITUUT (NL) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260117106-A1 | ANTI-FREEZE COMPOSITION BASED ON 2D AMPHIPHILIC PEPTIDE NANOSTRUCTURES | YBX1, MAFK, MEF2D | KMT2A 3627/4885HTT 2632/4885EPHX2 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.